Summarized by Masters of Longevity from Longevity Docs News.
Peptide compounding policy developments: a news article explaining a proposed FDA interim policy under White House review and its implications for clinic and online peptide use.
Key Takeaways
- FDA transmitted an 'Interim Access Policy for Compounding Using Certain Peptides' to the White House OIRA on October 14, pending review.
- FDA explicitly stated that retatrutide cannot be used in compounding and issued August warning letters against online sellers of the drug.
- Lilly has filed six lawsuits and reported over 14,000 online listings for retatrutide while its TRIUMPH-1 trial showed a 28.3% mean weight loss at 12 mg versus 2.2% for placebo.
